and 1Glaxo Group Research Limited, Ware, Hertfordshire SG12 ODP 1 The effect of twice-daily dosing with propranolol on the pharmacokinetics and pharmacodynamics of a single oral dose of sumatriptan was investigated in 10 healthy male subjects. 2 Each subject received 7 days dosing with propranolol (80 mg twice daily) plus a single dose of sumatriptan (300 mg orally) on day 7; on another separate occasion, placebo was administered for 7 days plus a single dose of sumatriptan on day 7. There was at least a 7 day washout interval between the two periods of dosing. Pulse and blood pressure were measured up to 10 h after dosing with sumatriptan and blood samples were taken up to 26 h post-dose. 3 Propranolol had no significant effect on any of the derived pharmacokinetic parameters of sumatriptan. The appropriate average parameter values in the presence of propranolol were, respectively: Cmax (120 ng ml-' vs 126 ng ml-'), tmax (4.5 h vs 3.0 h), AUC (580 ng ml-' h vs 566 ng ml-1 h), t½,,z (1.9 h vs 1.8 h).
Introduction
Sumatriptan (GR43175, Figure la) is a selective 5-HT1like receptor agonist (Brittain et al., 1989) . Several studies have demonstrated that sumatriptan is effective in the treatment of acute migraine attacks (Dahlos et al., 1989; Ferrari et al., 1989) . Many patients who suffer from frequent migraine attacks are given prophylactic therapy with propranolol or another ,-adrenoceptor antagonist. Thus, sumatriptan and propranolol may be prescribed concomitantly.
Sumatriptan is mainly cleared by oxidative metabolism, the major metabolite being the indoleacetic acid analogue (Figure lb) . Extensive pre-systemic metabolism occurs after oral dosing, resulting in a low oral bioavailability of drug. Propranolol inhibits the oxidative metabolism of several drugs (Bax et al., 1981) and thus might decrease the metabolic clearance and increase the oral bioavailability of sumatriptan. The objectives of this study were to determine whether twice-daily repeat oral dosing with propranolol (80 mg) has any effects on the pharmacokinetics or pharmacodynamics (pulse rate and blood pressure) of orally administered sumatriptan (300 mg). A 160 mg daily dose of propranolol was chosen because the majority of migraine patients, who respond to prophylactic treatment with propranolol, require a dose less than 160 mg daily.
Methods

Study design and procedures
Ten healthy male volunteers, aged 22-38 years (median 24 years) and weighing 60.0-88.9 kg (median 75.0 kg), were selected for study. The subjects were not taking regular medication and all had a normal ECG and normal renal and hepatic function as assessed by routine laboratory safety tests. Each subject gave written informed consent and ethical approval was granted by Mersey Regional Ethics Committee.
The study was a double-blind, two-way, randomised, cross-over design. Sumatriptan (300 mg) was administered by mouth on two occasions at least 14 days apart. Dispersible tablets (3 x 100 mg) were dissolved in 100 ml water and swallowed, followed by a further 150 ml water after rinsing the dosing container. Each study day was preceded by 6 days dosing with propranolol 80 mg twicedaily or matching placebo. Propranolol or matching placebo was given 1 h before and 11 h after administration of sumatriptan on the study day.
On each study day, subjects attended after an overnight fast. An indwelling, intravenous cannula was inserted into a suitable forearm vein and kept patent with heparinised saline (50 units per ml). Blood samples (6 ml) were withdrawn before dosing and at 15, 30 and 45 minand 1, 1.5,2,2.5,3,3.5,4,4.5,5,6,8, 10, 12,24 and 26 h post-dosing for determination of plasma sumatriptan concentrations. Plasma was stored at -20°C pending analysis. Additional blood was withdrawn before the penultimate propranolol or placebo dose and at 0.5, 1, 2 and 4 h post-dose for plasma propranolol measurements.
A routine laboratory safety screen (clinical chemistry, biochemistry and urinalysis) was performed before dosing and 24 h post dosing on each study day.
Pulse rate and blood pressure measurements were made after sitting for 2 min. The right arm was used and supported level with the heart. Recordings were made before dosing and at 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 10 h after administration of sumatriptan, using a Copal UA-251 semi-automatic digital sphygmomanometer.
No alcohol or caffeine containing drinks were permitted on the study days. Subjects were given 200 ml of diluted orange squash 2 h after dosing with sumatriptan. A light lunch was provided at 4 h post dosing and an evening meal at 10 h post dosing. These meals were the same on each study day. There were no restrictions on fluid intake after lunch.
Analytical procedure
Sumatriptan concentrations were measured using a validated h.p.l.c. method with electrochemical detection. A 5 ,um, Spherisorb ODS-1, 12.5 cm x 4.6 mm i.d. column was used with phosphate buffer (0.05 M, pH 7): methanol (38:62 by volume) as a mobile phase at a flow rate of 1.5 ml min-'. The lower limit of quantification was 1 ng ml-'. The inter-day precision during analysis of the samples was 8.6% (n = 12) at 4 ng ml-l and 11.3% (n = 14) at 25 ng ml-'. The corresponding accuracies were approximately 97% and 95%, respectively.
Propranolol concentrations were measured using a validated h.p.l.c. method with fluorescence detection, which was a modification of the method of Lagerstrom & Persson (1978) . A 5 ,um, Ultrasphere Octyl, 25 cm x 4.6 mm i.d. column was used with phosphate buffer (0.075 M, pH 3.2):acetonitrile (74.5:25.5 by volume) as mobile phase at a flow rate of 1.5 ml min-'. The lower limit of quantification was 5 ng ml-'. The inter-day precision during anlaysis of the samples was 7% (n = 10) at 5 ng ml-' and 4% (n = 9) at 99 ng ml-'. The corresponding accuracies were approximately 100% and 98%, respectively.
Pharmacokinetic analysis and statistical methods
The maximum sumatriptan plasma concentration (Cmax) and the time of its occurrence (tmax) were obtained directly from the data. The area under the plasma concentration-time curve from zero to 12 h post-dose (AUC) was calculated by a combination of linear and log trapezoidal methods. The linear trapezoidal method was used when plasma concentrations were rising and the log trapezoidal method when concentrations were declining. The plasma rate-constant up to 12 h post-dose (X) was estimated by log-linear regression and the corresponding half-life (t½l,) was also calculated.
The plasma sumatriptan concentrations at 24 and 26 h after dosing were excluded from the pharmacokinetic analysis. This was done because the concentrations at the later times were, in general, close to the limit of quantification for the assay method.
Cmax, AUC and X were analysed using analysis of variance, allowing for effects due to sequences, subjects within sequence, periods and treatments. The variances of Cmax and AUC tend to increase as their mean values increase. Therefore, these parameters were analysed after transformation to a logarithmic scale to compensate for non-constant variance (Pabst & Jaeger, 1990) . The tmax values were analysed using the non-parametric method of Koch (1972) . The measure of average used for each pharmacokinetic parameter reflected the statistical analysis carried out. Thus, geometric mean was used for Cmax and AUC, arithmetic mean for X, harmonic mean for tv½ and median for tmax.
Pulse rate and blood pressure data were analysed by analysis of variance, appropriate to a two-period crossover design. Weighted mean responses were calculated by dividing the area under the response-time profile, obtained using linear trapezoidal integration, by the time period (i.e. 10 h). The pre-sumatriptan values were taken as the mean of three pre-treatment values and were used as the zero time values. Differences between the weighted mean responses and the zero time values were compared between treatments.
Results
The plasma sumatriptan profiles and the sumatriptan pharmacokinetic parameters, in the presence of propranolol or placebo, are shown in Figure 2 and Table 1 , respectively. Propranolol had no significant effect on the pharmacokinetics of sumatriptan at the 5% level of significance. However, the effect on tmax was of borderline significance (P = 0.06).
All subjects had detectable plasma propranolol concentrations during the period of propranolol treatment. The median pre-dose propranolol concentration on day 7 was 27 ng ml-' (range 9-129 ng ml-'). The median propranolol concentration 2 h after dosing was 80 ng ml-' (range 48-240 ng ml-'). 
.' :. Figure 2 Plots of the median plasma sumatriptan concentration-time profiles after oral administration of 300 mg drug, in the presence (A) or absence (@) of propranolol.
The pulse rate and blood pressure weighted mean responses (0-10 h) and post/pre-sumatriptan differences are shown in Table 2 . As expected, pulse rate and blood pressure were significantly lower during propranolol treatment. For example, the mean pre-sumatriptan systolic blood pressure reading was 109 mm Hg during propranolol treatment and 120 mm Hg while receiving placebo. Propranolol had no significant effect on the pulse and blood pressure changes following an oral dose of sumatriptan.
No serious adverse reactions were noted. Six subjects reported minor adverse effects following sumatriptan while receiving placebo and five while receiving propranolol. Headache, nausea, malaise, lack of concentration, feeling faint and head or neck tingling were reported.
Discussion
Repeat dosing with propranolol had no significant effect on the pharmacokinetics of a single oral dose of sumatriptan. Average values for Cmax, AUC and tl½ were similar in the presence or absence of propranolol. In the presence of propranolol, tmax tended to occur earlier (P = 0.06). However, the multiple peak plasma concentrations which occur after oral dosing with sumatriptan make tma an unreliable parameter. Up to approximately 12 h post dosing sumatriptan plasma concentrations declined with a mean plasma half-life of approximately 2 h. At times later than this, most subjects showed evidence of a longer terminal half-life, which could not be reliably quantified.
The dose of propranolol used in this study was enough to produce a significant pharmacological effect in all subjects, as demonstrated by the fall in pulse rate and blood pressure. For the prophylactic treatment of migraine, most patients who respond to propranolol do so at a dose lower than 160 mg daily. Occasional patients may require 320 mg daily. This raises the possibility that higher doses of propranolol might alter the pharmacokinetics of sumatriptan. While such an effect cannot be excluded, the probability of a clinically important interaction occurring is small. Previous interaction studies which have shown an effect of propranolol on the pharmacokinetics of other drugs have used a dose of 160 mg daily or less (Bax et al., 1981) .
In the presence of placebo, a small increase in blood pressure was seen after dosing with sumatriptan. After baseline correction, the magnitude of this effect was no different in the presence or absence of propranolol. The rise in blood pressure could be due either to sumatriptan or to diurnal variation. However, in a previous betaadrenoceptor antagonist interaction study in which blood pressure recordings were made over a similar period, it was found that a fall occurred over the first few hours (Scott et al., 1984) . This suggests that oral sumatriptan may cause a small increase in blood pressure.
This study found no evidence that propranolol has any effect on the pharmacokinetics or pharmacodynamics of Table 2 Pulse rate and blood pressure weighted mean responses (0-10 h) (WMR) and post/pre-sumatriptan (S) differences with confidence intervals following oral sumatriptan sumatriptan. Although the dose of sumatriptan used in this study was three times the recommended therapeutic dose, no serious adverse reactions were observed.
Therefore, no alteration in the sumatriptan dosage should be necessary for migraine patients taking propranolol prophylactic therapy.
